The notable prevalence of ESBL- and carbapenemase-producing E. coli among IBS patients may significantly affect patient outcomes, underscoring the need for targeted antibiotic stewardship and monitoring of biofilm-forming, drug-resistant strains.
Ramezani et al. (Wed,) studied this question.